600201.SHG Jinyu Bio-Technology Co Ltd
- Market cap
- CNY 14.0B
- P/E
- 84.0x
- P/B
- 2.50x
- ROE
- 5.7%
- Dividend yield
- 0.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600201.SHG undervalued?
Graham numberThe Graham number of Jinyu Bio-Technology Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jinyu Bio-Technology Co Ltd fundamental analysis
No fundamental analysis for Jinyu Bio-Technology Co Ltd yet.
Jinyu Bio-Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth disease type O and A bivalent inactivated, porcine circovirus type 2 baculovirus vecto…
Full company profileJinyu Bio-Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jinyu Bio-Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.52B | 1.90B | 1.90B | 1.13B | 1.58B | 1.78B | 1.53B | 1.60B | 1.26B | 1.40B | 1.67B |
| Gross Profit | 1.17B | 1.50B | 1.34B | 662M | 960M | 1.09B | 831M | 930M | 658M | 748M | 928M |
| Operating Income | 772M | 1.03B | 889M | 254M | 478M | 415M | 255M | 315M | 125M | 120M | 445M |
| EBITDA | 802M | 1.03B | 897M | 319M | 581M | 585M | 451M | 437M | 247M | 364M | 379M |
| Net Income | 645M | 870M | 754M | 221M | 406M | 382M | 211M | 284M | 109M | 100M | 301M |
| EPS | 0.61 | 0.76 | 0.66 | 0.20 | 0.36 | 0.34 | 0.19 | 0.26 | 0.10 | 0.09 | 0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 4.35B | 5.68B | 6.31B | 5.59B | 6.28B | 6.60B | 6.39B | 6.87B | 6.76B | 6.61B | 6.62B |
| Total Liabilities | 595M | 1.21B | 1.09B | 717M | 1.02B | 1.04B | 1.04B | 1.22B | 1.35B | 1.06B | 1.23B |
| Shareholders' Equity | 3.75B | 4.47B | 5.03B | 4.65B | 4.98B | 5.27B | 5.07B | 5.37B | 5.31B | 5.37B | 5.27B |
| Cash & Short-term Investments | 2.40B | 2.45B | 1.73B | 1.78B | 2.16B | 1.52B | 1.45B | 1.75B | 1.18B | 1.26B | 1.47B |
| Total Debt | 500K | 2.58M | 2.58M | 40.1M | 98.0M | 776K | 10.9M | 2.73M | 16.3M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 756M | 891M | 422M | 405M | 700M | 533M | 345M | 415M | 290M | 316M | - |
| Capital Expenditure | 134M | 402M | 545M | 307M | 228M | 373M | 190M | 273M | 89.7M | 121M | 79.4M |
| Free Cash Flow | 622M | 489M | -123M | 97.9M | 471M | 160M | 155M | 142M | 200M | 195M | 206M |
| Ratios | |||||||||||
| ROE | 17.2% | 19.5% | 15.0% | 4.8% | 8.2% | 7.3% | 4.2% | 5.3% | 2.1% | 1.9% | 5.7% |
| ROA | 14.8% | 15.3% | 12.0% | 4.0% | 6.5% | 5.8% | 3.3% | 4.1% | 1.6% | 1.5% | 4.6% |
| Net Profit Margin | 42.5% | 45.8% | 39.8% | 19.6% | 25.7% | 21.5% | 13.8% | 17.7% | 8.7% | 7.2% | 18.1% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.01x | 0.02x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jinyu Bio-Technology Co Ltd dividends
- Dividend yield
- 0.24%
- Forward dividend
- 0.04 CNY
- Payout ratio
- 33.3%
- Ex-dividend date
- Jun 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 33.3M | 0.03 | 33.3% |
| 2024 | CNY 89.4M | 0.08 | 82.0% |
| 2023 | CNY 66.8M | 0.06 | 23.6% |
| 2022 | CNY 121M | 0.11 | 57.2% |
| 2021 | CNY 135M | 0.12 | 35.3% |
| 2020 | CNY 67.1M | 0.06 | 16.5% |
| 2019 | CNY 386M | 0.35 | 174.8% |
| 2018 | CNY 265M | 0.23 | 35.1% |
| 2017 | CNY 309M | 0.27 | 35.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 25, 2018.
Who owns Jinyu Bio-Technology Co Ltd
- Insiders 21.53%
- Institutions 8.95%
- Public & others 69.52%
- Shares outstanding 1.11B
- Free float 926M
Jinyu Bio-Technology Co Ltd company profile
- Company name
- Jinyu Bio-Technology Co Ltd
- Ticker
- 600201.SHG
- ISIN
- CNE000000Y37
- Exchange
- Shanghai Stock Exchange
- Listed since
- Nov 24, 1998
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,881
- Fiscal year end
- December
- Address
- Shaerqin Industrial Park, Hohhot, China, 010111
- Phone
- 86 47 1816 6957
- Website
- jinyu.com.cn
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth disease type O and A bivalent inactivated, porcine circovirus type 2 baculovirus vector inactivated, porcine reproductive and respiratory syndrome chimeric virus live and inactivated, and swine fever live, transmissible gastroenteritis in pigs, swine live influenza bivalent, bovine viral diarrhea/mucosal disease, infectious rhinitis two-dose inactivated, brucella gene-deleted live, brucellosis live, inactivated emphysema and gangrene, ruminant disease live, newcastle disease, infectious bursal disease trivalent inactivated, recombinant avian influenza virus trivalent inactivated, infectious bronchitis symptoms, egg drop syndrome type 4 quadrivalent inactivated infectious bronchitis, canine distemper and parvovirus bivalent live, feline panleukopenia calicivirus disease trivalent inactivated trivalent, and inactivated rabies vaccines. Further, the company manufactures and sells biological pharmaceutical preparations, and chemical reagents and auxiliaries; develops biotechnology; transfer and consulting services; advanced medical equipment and instruments; import and export of goods and technology; and provision of property management services. Additionally, it is involved in real estate activities; biochemical products; planting; hotel management services; internet information service finance; biotechnology promotion services; owner-owned house for rent; mechanical equipment processing; investment management; management, meal, technical, and medical services; and trading activities. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.
Jinyu Bio-Technology Co Ltd management
4- Ms. Jing ZhangVice Chairman & President · born 1983
- Mr. Kai LiChief Financial Officer · born 1992
- Li Wen WangAccounting Supervisor
- Ms. Li Xia ZhaoVice President · born 1975